Illumina, Inc.  

(Public, NASDAQ:ILMN)   Watch this stock  
Find more results for ILMN
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 145.12 - 213.33
Open     -
Vol / Avg. 0.00/1.35M
Mkt cap 29.54B
P/E 70.77
Div/yield     -
EPS 2.90
Shares 144.10M
Beta 0.83
Inst. own 95%
Jul 21, 2015
Q2 2015 Illumina Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 10, 2015
Illumina Inc at Goldman Sachs Healthcare Conference - 1:00PM EDT - Add to calendar
Jun 3, 2015
Illumina Inc at Bank of America Merrill Lynch Global Technology Conference - 11:30AM EDT - Add to calendar
May 27, 2015
Illumina Inc Annual Shareholders Meeting - 1:00PM EDT - Add to calendar
May 13, 2015
Illumina Inc at Bank of America Merrill Lynch Health Care Conference
Apr 21, 2015
Q1 2015 Illumina Inc Earnings Call - Webcast
Apr 21, 2015
Q1 2015 Illumina Inc Earnings Release
Mar 4, 2015
Illumina Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 25.37% 18.98%
Operating margin 32.70% 27.65%
EBITD margin - 29.49%
Return on average assets 16.03% 11.11%
Return on average equity 35.52% 23.59%
Employees 3,700 -
CDP Score - -


5200 Illumina Way
SAN DIEGO, CA 92122-4616
United States - Map
+1-858-2024500 (Phone)
+1-858-2024766 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. The Company is organized in two business segments: Life Sciences and Diagnostics. Its Life Sciences business unit includes all products and services related to the research market, namely the product lines based on its sequencing, BeadArray, VeraCode, and real-time PCR technologies. Its Diagnostics business unit focuses on molecular diagnostics. Its customers include genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies. In July 2014, the Company acquired Myraqa, a regulatory and quality consulting firm specializing in IVDs, particularly companion diagnostics.

Officers and directors

William H. Rastetter Ph.D. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Francis A. deSouza President, Director
Age: 44
Bio & Compensation  - Reuters
Jay T. Flatley Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Marc A. Stapley Chief Financial Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
David R. Walt Ph.D. Chairman - Scientific Advisory Board, Independent Director
Age: 62
Bio & Compensation  - Reuters
Mostafa Ronaghi Ph.D. Chief Technology Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
Charles E. Dadswell Senior Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Nicholas J. Naclerio Ph.D. Senior Vice President, Corporate Development & General Manager - Enterprise Informatics
Age: 53
Bio & Compensation  - Reuters
Paul L. Bianchi Senior Vice President - Human Resources
Age: 53
Bio & Compensation  - Reuters
Christian O. Henry Senior Vice President, Chief Commercial Officer
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance